Mo Abdawa

Mo Abdawa

Applied Microbiology, Centre Universitaire de Mila, Mila, Algeria
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
HEhala mohamed elhacimi
hala mohamed elhacimi
MAMohamed Mahmoud Mohamed El Alem
Mohamed Mahmoud Mohamed El Alem
EHEsma Haimoudane
Esma Haimoudane
CYCheikh Yebouk
Cheikh Yebouk
JPJannie Pedersen
Jannie Pedersen
MAMohamed Vall Mohamed Abdellahi
Mohamed Vall Mohamed Abdellahi
Background: The Hepatitis B virus (HBV) vaccine is used worldwide as an efficient tool to prevent the occurrence of chronic HBV infection and the subsequent liver disease. However, despite decades of vaccination campaigns, millions of new infections are still reported every year. Here, we aimed to assess the nationwide HBV vaccination coverage in Mauritania as well as the presence of protective levels of the antibodies against HBV surface antigen (HBsAb) following vaccination in a sample of children immunized as infants. Methods: To evaluate the frequency of fully vaccinated and seroprotected children in Mauritania, a prospective serological study was conducted in the capital. First, we evaluated the pediatric HBV vaccine coverage in Mauritania between 2015 and 2020. Then, we examined the level of antibodies against HBV surface antigen (HBsAb) in 185 fully vaccinated children (aged 9 months to 12 years) by ELISA using the VIDAS hepatitis panel for Minividas (Biomerieux). These vaccinated children were sampled in 2014 or 2021. Results: In Mauritania, between 2016 and 2019, more than 85% of children received the complete HBV vaccine regimen. While 93% of immunized children between 0 and 23 months displayed HBsAb titer >10 IU/L, the frequency of children with similar titers decreased to 63, 58 and 29% in children aged between 24–47, 48–59 and 60–144 months, respectively. Conclusions: A marked reduction in the frequency of HBsAb titer was observed with time, indicating that HBsAb titer usefulness as marker of protection is short lived and prompting the need for more accurate biomarkers predictive of long-term protection.

12 February 2026 in Diseases
Verified
Journal Article
Open access
PDF file
MAMo Abdawa
Mo Abdawa
MHMohamed Hemeyine
Mohamed Hemeyine
Isabelle CheminIsabelle Chemin
Isabelle Chemin
FLFrançoise Lunel-Fabiani
Françoise Lunel-Fabiani
MAMohamed Vall Mohamed Abdellahi
Mohamed Vall Mohamed Abdellahi
Background: Hepatitis B virus (HBV) infection remains highly endemic in sub-Saharan Africa, where hepatitis delta virus (HDV) co-infection substantially worsens liver disease outcomes. Mauritania has long been suspected to be a high-burden setting for HBV-HDV co-infection, yet contemporary data describing its clinical and virological impact remain limited. Methods: We conducted a hospital-based cross-sectional study at the National Institute of Hepato-Virology (INHV) in Nouakchott, including 401 HBsAg-positive patients. Demographic, clinical, biological, and virological data were collected. HDV serology and RNA testing were performed when available. Liver disease severity, including cirrhosis and hepatocellular carcinoma (HCC), was assessed using clinical, biological, and imaging criteria. Results: HDV antibodies were detected in 31.9% of HBsAg-positive patients, confirming Mauritania as a hyper-endemic area for HDV. HDV co-infection was strongly associated with advanced liver disease, with HDV antibodies present in 86.4% of cirrhotic patients and 82.4% of those with HCC. Patients with HDV infection frequently exhibited suppressed HBV DNA levels, reflecting viral interference. A substantial proportion of patients presented with decompensated cirrhosis or HCC at diagnosis, and nearly 70% were treatment-naïve. Overall, HDV co-infection emerged as the principal driver of severe liver disease in this cohort. Conclusions: HBV/HDV co-infection is highly prevalent in Mauritania and is associated with a wide clinical spectrum ranging from asymptomatic infection to decompensated cirrhosis and hepatocellular carcinoma. HDV co-infection is the principal driver of severe liver disease, often occurring despite low or undetectable HBV DNA levels. Systematic HDV screening among all HBsAg-positive individuals is urgently needed to improve risk stratification, guide therapeutic decisions, and reduce liver-related morbidity and mortality.

30 October 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MAMo Abdawa
Mo Abdawa
RTRayana Maryse Toyé
Rayana Maryse Toyé
MAMohamed Vall Mohamed Abdellahi
Mohamed Vall Mohamed Abdellahi
MHMohamed Hemeyine
Mohamed Hemeyine
AEAhmed Elbara
Ahmed Elbara
FLFrançoise Lunel-Fabiani
Françoise Lunel-Fabiani
Chronic hepatitis B (CHB) is highly endemic in Mauritania, and co‑infection with hepatitis delta virus (HDV) may worsen liver outcomes. We characterized circulating hepatitis B virus (HBV) and HDV strains and assessed the clinical impact of HDV co‑infection among HBsAg‑positive patients in Nouakchott. A total of 165 adults with CHB were enrolled at the National Institute of Hepato-Virology. Demographic/clinical data, serological and molecular tests, ultrasound, and fibrosis estimates (APRI, FIB-4) were collected. HBV DNA was quantified by real-time PCR; HDV RNA was measured mainly by RT-ddPCR. HBV and HDV were Sanger-sequenced. HBV DNA was detectable in 146/165 (88.5%) with median 2197.25 IU/mL; 75/165 (45.45%) exceeded 2000 IU/mL. Total anti-HDV antibodies were found in 68/112 (60.7%) tested; HDV RNA was quantified in 130/165 patients and detected in 34/130 (26.15%) with median 72,271 IU/mL, including 34/68 (50%) of anti-HDV–positive patients. HDV-RNA positivity was associated with symptoms, higher AST/ALT/AFP/APRI/FIB-4, lower HBV DNA detectability, and increased cirrhosis/HCC and treatment use ( p ≤ 0.004). HBV genotypes were D (36/65, 55.4%), including 11 isolates (16.9%) assigned to subgenotype D8, a D/E recombinant lineage first described in Niger; E (21/65, 32.3%); and A (8/65, 12.3%). HDV genotyping ( n = 21) showed mainly genotype 1 and two genotype 5 isolates. An rtA181S substitution in the polymerase reverse-transcriptase domain and a naturally occurring altered YMDD motif (rtY203N) were detected. Whole-genome analysis revealed co-circulation of HBV genotypes A (A1/A2), D (D1/D4), E, and recombinant D/E strains, with high conservation across coding regions and absence of widespread antiviral resistance in these Mauritanian patients’ samples. HDV co‑infection is frequent among Mauritanian patients with CHB and is associated with more severe liver injury. HBV genotype D predominates, with presence of inter‑genotype recombinations and HDV genotypes are mainly genotype 1. These findings support routine HDV screening, timely antiviral access, and improved HBV vaccination coverage- including the birth dose- to slow disease incidence and progression in Mauritania.